Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China39 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, Sulfatidosis, brain disorder, central nervous system disorder, demyelinating disease, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, metachromatic leukodystrophy, nervous system disorder, sphingolipidosis | Not yet recruiting | Not applicable | 2026-09-01 | NCT07046338 | |
| 4SCAR19U T Cells Targeting B Cell Malignancies | B Cell Malignancies | Not yet recruiting | Phase 1 | 2026-09-01 | NCT05995015 | |
| IT and IV Lentiviral Gene Therapy for X-ALD | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Peroxisomal Disorders, X-linked disease, adrenal gland disorder, adrenocortical insufficiency, adrenoleukodystrophy, brain disorder, central nervous system disorder, demyelinating disease, endocrine system disorder, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, metabolic disease, nervous system disorder | Not yet recruiting | Not applicable | 2026-09-01 | NCT03727555 | |
| Lentiviral FVIII Gene Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Not yet recruiting | Phase 1 | 2026-09-01 | NCT03217032 | |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07501156 | |
| cfMSC Therapy for Diabetes | Insulin Resistance, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07495956 | |
| cfMSC Stem Cell Therapy Targeting COPD | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07477600 | |
| Combination Immunotherapy Targeting Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06739226 | |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, plasmacytoma, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 | 2026-08-27 | NCT06435910 | |
| Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells | autoimmune disease, immune system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06435897 | |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, plasmacytoma, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06429150 | |
| Universal CAR-T Cells Targeting AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-08-27 | NCT05995041 | |
| Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Not yet recruiting | Not applicable | 2026-08-27 | NCT03351829 | |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT03271632 | |
| SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Primary Immunodeficiency Diseases, X-Linked Combined Immunodeficiency Diseases, X-linked disease, hereditary disease, immune system disorder, inborn error of immunity, severe combined immunodeficiency | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT03217617 | |
| Universal CAR-T Cells Targeting Multiple Myeloma | Multiple Myeloma in Remission | Not yet recruiting | Phase 1 | 2026-08-26 | NCT06006741 | |
| Universal 4SCAR7U Targeting CD7-positive Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-08-26 | NCT05995028 | |
| CAR-T Cells Targeting Autoimmune Diseases | autoimmune disease, immune system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05459870 | |
| GD2/CD70 Bi-specific CAR-T Cell Therapy | neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05438368 | |
| GD2/PSMA Bi-specific CAR-T Cell Therapy | Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05437315 | |
| CD19/70 Bi-specific CAR-T Cell Therapy | B Cell Malignancies | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05436496 | |
| CD19/22 Bi-specific CAR-T Cell Therapy | B Cell Malignancies | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05432882 | |
| Combination Immunotherapy Targeting Sarcomas | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT04433221 | |
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 | Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT04432649 | |
| PSMA-specific CAR-T Cell Therapy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT04429451 |